RxDoctor Payments Data

Abigail Lukens, DO

Family Medicine · Ventura, CANPI 1588014658

Payments from drug & device makers

$459in general payments, 2019–2025

Across 25 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$82
  • Amgen$71
  • Lilly USA, LLC$63
  • Merck$46
  • Ascend Therapeutics US, LLC$44
  • Novo Nordisk$31
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim4$82
Amgen4$71
Lilly USA, LLC4$63
Merck3$46
Ascend Therapeutics US, LLC2$44
Novo Nordisk2$31
Radius Health, Inc.1$29
Sanofi Pasteur Inc.1$27
Abbott1$22
AstraZeneca1$15
Johnson & Johnson1$15
GSK1$15

How this compares

$459 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$193,858
Medicare patients
397
Services billed
2,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$36,225
OzempicSemaglutide20$35,377
JardianceEmpagliflozin18$29,823
Atorvastatin Calcium297$3,034
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$2,657
Wixela InhubFluticasone Propion/Salmeterol14$2,577
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$2,526
Levothyroxine Sodium228$2,491
PremarinEstrogens, Conjugated12$2,428
Esomeprazole Magnesium30$1,996
Estradiol40$1,899
Losartan Potassium165$1,864
Tamsulosin Hcl97$1,849
Amlodipine Besylate172$1,466
Duloxetine Hcl53$1,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$35,37720 claims
Boehringer IngelheimJardiance$82$29,82318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →